您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > VTP50469
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
VTP50469
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
VTP50469图片
CAS NO:2169916-18-9
包装与价格:
包装价格(元)
2 mg电议
5 mg电议
10 mg电议
25 mg电议
50 mg电议
100 mg电议
200 mg电议
1 mL*10 mM(in DMSO)电议

产品介绍
VTP50469 是一种高选择性和口服活性的Menin-MLL相互作用抑制剂,具有有效的抗白血病活性,Ki为 104 pM。

产品描述

VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.

体外活性

VTP50469 more potently and rapidly inhibits cell proliferation in a concentration-dependent manner in MLL-r cell lines carrying (MOLM13 with IC50 of 13 nM), THP1 with IC50 of 37 nM, NOMO1 with IC50 of 30 nM, ML2 (IC50 of 16 nM), EOL1 (IC50 of 20 nM), and murine MLL-AF9 cells (IC50 of 15 nM)) and ALL (KOPN8 (IC50 of 15 nM), HB11;19 (IC50 of 36 nM), MV4;11 (IC50 of 17 nM), SEMK2 (IC50 of 27 nM), and RS4;11 (IC50 of 25 nM)) cell lines. At early timepoints MLL-r B cell ALL (B-ALL) cell lines, but not MLL-r AML cell lines, underwent apoptosis in response to VTP50469 in a dose-dependent manner. MLL-r AML cell lines underwent dose-dependent differentiation starting at 4-6 days of exposure to VTP50469. VTP50469 replaces Menin in protein complexes and suppresses the chromatin occupancy of MLL on certain genes. Loss of MLL binding leads to changes in gene expression, differentiation, and apoptosis [1].

体内活性

In NSG mice, VTP50469 (15-60 mg/kg; p.o.; twice a day; for 28 days) treatment is highly efficacious across all dosage levels and all treatment groups have a significant survival advantage. Mice dosed at 30 and 60 mg/kg VTP50469 extends survival advantage [1].

Cas No.

2169916-18-9

分子式

C32H47FN6O4S

分子量

630.82

储存和溶解度

DMSO:125 mg/mL (198.15 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years